Giovanni Monteleone

List of Publications by Year
in descending order

290	18,173	11651 70	16650 123
papers	citations	h-index	g-index

294	294	294	19498
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cutting Edge: TGF-Î² Induces a Regulatory Phenotype in CD4+CD25â^' T Cells through Foxp3 Induction and Down-Regulation of Smad7. Journal of Immunology, 2004, 172, 5149-5153.	0.8	1,060
2	Immunity, Inflammation, and Allergy in the Gut. Science, 2005, 307, 1920-1925.	12.6	977
3	Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology, 1997, 112, 1169-1178.	1.3	533
4	Blocking Smad7 restores TGF-Î²1 signaling in chronic inflammatory bowel disease. Journal of Clinical Investigation, 2001, 108, 601-609.	8.2	517
5	Aryl Hydrocarbon Receptor-Induced Signals Up-regulate IL-22 Production and Inhibit Inflammation in the Gastrointestinal Tract. Gastroenterology, 2011, 141, 237-248.e1.	1.3	475
6	Th17-type cytokines, IL-6 and TNF-Î± synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene, 2015, 34, 3493-3503.	5.9	426
7	Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohnâ€™s Disease. New England Journal of Medicine, 2015, 372, 1104-1113.	27.0	366
8	Differential regulation of interleukin 17 and interferon Â production in inflammatory bowel disease. Gut, 2009, 58, 1629-1636.	12.1	299
9	Interleukin-21 enhances T-helper cell type I signaling and interferon-Î³ production in Crohnâ€™s disease. Gastroenterology, 2005, 128, 687-694.	1.3	283
10	Bioactive IL-18 expression is up-regulated in Crohn's disease. Journal of Immunology, 1999, 163, 143-7.	0.8	267
11	The gutâ€skin axis in health and disease: A paradigm with therapeutic implications. BioEssays, 2016, 38, 1167-1176.	2.5	264
12	IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes. Journal of Immunology, 2007, 178, 732-739.	0.8	256
13	Up-Regulation of IL-17 Is Associated with Bioactive IL-8 Expression inHelicobacter pylori-Infected Human Gastric Mucosa. Journal of Immunology, 2000, 165, 5332-5337.	0.8	250
14	Regulation of Gut Inflammation and Th17 Cell Response by Interleukin-21. Gastroenterology, 2008, 134, 1038-1048.e2.	1.3	244
15	Regulation of Homeostasis and Inflammation in the Intestine. Gastroenterology, 2011, 140, 1768-1775.	1.3	233
16	IL-23/IL-17 axis in IBD. Inflammatory Bowel Diseases, 2010, 16, 1808-1813.	1.9	221
17	Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nature Medicine, 2009, 15, 1013-1015.	30.7	183
18	Inhibition of Smad7 With a Specific Antisense Oligonucleotide Facilitates TGF-Î²1â€“Mediated Suppression of Colitis. Gastroenterology, 2006, 131, 1786-1798.	1.3	182

#	Article	IF	Citations
19	Transforming growth factor Â signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut, 2009, 58, 777-789.	12.1	179
20	Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?. Journal of Crohn's and Colitis, 2020, 14, 1334-1336.	1.3	162
21	Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut, 2006, 55, 1774-1780.	12.1	159
22	A Functional Role for Interleukin-21 in Promoting the Synthesis of the T-Cell Chemoattractant, MIP-3Î±, by Gut Epithelial Cells. Gastroenterology, 2007, 132, 166-175.	1.3	152
23	Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut, 2008, 57, 887-892.	12.1	150
24	ILâ€21 regulates experimental colitis by modulating the balance between T_{reg} and Th17 cells. European Journal of Immunology, 2007, 37, 3155-3163.	2.9	149
25	Smad7 Controls Resistance of Colitogenic T Cells to Regulatory T Cell-Mediated Suppression. Gastroenterology, 2009, 136, 1308-1316.e3.	1.3	147
26	Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Frontiers in Microbiology, 2019, 10, 1655.	3.5	146
27	Functional Modulation of Crohnâ€™s Disease Myofibroblasts by Anti-Tumor Necrosis Factor Antibodies. Gastroenterology, 2007, 133, 137-149.	1.3	145
28	ILâ€23â€mediated regulation of ILâ€17 production in Helicobacter pyloriâ€infected gastric mucosa. European Journal of Immunology, 2008, 38, 470-478.	2.9	145
29	Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut, 2000, 47, 57-62.	12.1	135
30	A Failure of Transforming Growth Factor-Î²1 Negative Regulation Maintains Sustained NF-ÎºB Activation in Gut Inflammation. Journal of Biological Chemistry, 2004, 279, 3925-3932.	3.4	133
31	Smad7 in TGF-Î²-mediated negative regulation of gut inflammation. Trends in Immunology, 2004, 25, 513-517.	6.8	133
32	Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut, 2001, 48, 425-429.	12.1	129
33	Metagenomics Reveals Dysbiosis and a Potentially Pathogenic N. flavescens Strain in Duodenum of Adult Celiac Patients. American Journal of Gastroenterology, 2016, 111, 879-890.	0.4	128
34	Up-Regulation of the IL-12 Receptor Î²2 Chain in Crohnâ€™s Disease. Journal of Immunology, 2000, 165, 7234-7239.	0.8	127
35	Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. Journal of Experimental Medicine, 2011, 208, 2279-2290.	8.5	126
36	Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease. Molecular Therapy, 2012, 20, 870-876.	8.2	125

#	Article	IF	Citations
37	Interleukin-25 Inhibits Interleukin-12 Production and Th1 Cell-Driven Inflammation in the Gut. Gastroenterology, 2009, 136, 2270-2279.	1.3	121
38	Evidence for the Role of Interferon-alfa Production by Dendritic Cells in the Th1 Response in Celiac Disease. Gastroenterology, 2007, 133, 1175-1187.	1.3	119
39	Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut, 2002, 50, 186-190.	12.1	118
40	Interleukin-12 and Th1 immune response in Crohnâ€™s disease: Pathogenetic relevance and therapeutic inplication. World Journal of Gastroenterology, 2006, 12, 5606.	3.3	117
41	Characterization of IL-17Aâ€“Producing Cells in Celiac Disease Mucosa. Journal of Immunology, 2010, 184, 2211-2218.	0.8	106
42	STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment. International Journal of Molecular Sciences, 2018, 19, 1787.	4.1	106
43	Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opinion on Biological Therapy, 2019, 19, 1207-1217.	3.1	104
44	Post-transcriptional Regulation of Smad7 in the Gut of Patients With Inflammatory Bowel Disease. Gastroenterology, 2005, 129, 1420-1429.	1.3	101
45	Autocrine Regulation of IL-21 Production in Human T Lymphocytes. Journal of Immunology, 2008, 180, 1800-1807.	0.8	100
46	TGF-Î²1 and Smad7 in the regulation of IBD. Mucosal Immunology, 2008, 1, S50-S53.	6.0	99
47	Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3Î±. Blood, 2008, 112, 3339-3347.	1.4	99
48	Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology, 1999, 117, 1069-1077.	1.3	96
49	IL-21 Is Highly Produced in Helicobacter pylori-Infected Gastric Mucosa and Promotes Gelatinases Synthesis. Journal of Immunology, 2007, 178, 5957-5965.	0.8	94
50	Role of T_H17 cytokines in the control of colorectal cancer. OncoImmunology, 2013, 2, e26617.	4.6	92
51	Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflammatory Bowel Diseases, 2010, 16, 1332-1339.	1.9	89
52	Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?. Current Molecular Medicine, 2012, 12, 592-597.	1.3	87
53	Intestinal inflammation and colorectal cancer: a double-edged sword?. World Journal of Gastroenterology, 2011, 17, 3092-100.	3.3	87
54	Human Peyerâ€™s Patch T Cells Are Sensitized to Dietary Antigen and Display a Th Cell Type 1 Cytokine Profile. Journal of Immunology, 2000, 165, 5315-5321.	0.8	86

#	Article	IF	Citations
55	Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends in Immunology, 2008, 29, 290-294.	6.8	86
56	Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohnâ€™s Disease. PLoS ONE, 2013, 8, e54562.	2.5	86
57	Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut, 2004, 53, 1090-1095.	12.1	85
58	Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatology, The, 2020, 2, e255-e256.	3.9	85
59	Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut, 1998, 43, 735-736.	12.1	84
60	The Food Additive Maltodextrin Promotes Endoplasmic Reticulum Stressâ€“Driven Mucus Depletion and Exacerbates Intestinal Inflammation. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 457-473.	4.5	84
61	Blockade of transforming growth factor Â upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut, 2008, 57, 605-612.	12.1	83
62	Psoriasis: from pathogenesis to novel therapeutic approaches. Clinical Science, 2011, 120, 1-11.	4.3	83
63	New mediators of immunity and inflammation in inflammatory bowel disease. Current Opinion in Gastroenterology, 2006, 22, 361-364.	2.3	82
64	The role of interleukin 17 in Crohnâ€™s disease-associated intestinal fibrosis. Fibrogenesis and Tissue Repair, 2013, 6, 13.	3.4	82
65	Implication of Intestinal Barrier Dysfunction in Gut Dysbiosis and Diseases. Biomedicines, 2022, 10, 289.	3.2	81
66	Sodium chlorideâ€“enriched Diet Enhanced Inflammatory Cytokine Production and Exacerbated Experimental Colitis in Mice. Journal of Crohn's and Colitis, 2017, 11, 237-245.	1.3	80
67	Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochemical Pharmacology, 2008, 75, 668-676.	4.4	79
68	Interferon-Î± drives T cell-mediated immunopathology in the intestine. European Journal of Immunology, 2001, 31, 2247-2255.	2.9	78
69	The Dual Role of Inflammation in Colon Carcinogenesis. International Journal of Molecular Sciences, 2012, 13, 11071-11084.	4.1	77
70	The Dual Role of Smad7 in the Control of Cancer Growth and Metastasis. International Journal of Molecular Sciences, 2013, 14, 23774-23790.	4.1	76
71	Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 9-20.	17.8	76
72	The impact of COVID-19 pandemic in the colorectal cancer prevention. International Journal of Colorectal Disease, 2020, 35, 1951-1954.	2.2	76

#	Article	IF	Citations
73	The aryl hydrocarbon receptor in inflammatory bowel disease. Current Opinion in Gastroenterology, 2012, 28, 310-313.	2.3	75
74	Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunology, 2014, 7, 1467-1479.	6.0	75
75	Impact of Food Additives on Gut Homeostasis. Nutrients, 2019, 11, 2334.	4.1	75
76	Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease. Frontiers in Pharmacology, 2019, 10, 305.	3.5	74
77	Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Medicine, 2011, 9, 122.	5.5	73
78	Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer. International Journal of Molecular Sciences, 2013, 14, 17972-17985.	4.1	71
79	IL-12 and Th1 immune responses in human Peyer's patches. Trends in Immunology, 2001, 22, 244-247.	6.8	70
80	Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine and Growth Factor Reviews, 2009, 20, 185-191.	7.2	69
81	New players in the cytokine orchestra of inflammatory bowel disease. Inflammatory Bowel Diseases, 2007, 13, 1419-1423.	1.9	67
82	Plasma Cells in the Mucosa of Patients with Inflammatory Bowel Disease Produce Granzyme B and Possess Cytotoxic Activities. Journal of Immunology, 2014, 192, 6083-6091.	0.8	67
83	IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal Immunology, 2013, 6, 244-255.	6.0	64
84	Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends in Pharmacological Sciences, 2009, 30, 441-447.	8.7	63
85	Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. Gastroenterology, 2004, 126, 674-682.	1.3	62
86	Reduction of CD68+ Macrophages and Decreased IL-17 Expression in Intestinal Mucosa of Patients with Inflammatory Bowel Disease Strongly Correlate With Endoscopic Response and Mucosal Healing following Infliximab Therapy. Inflammatory Bowel Diseases, 2013, 19, 729-739.	1.9	62
87	Transforming Growth Factor-Î²1/Smad7 in Intestinal Immunity, Inflammation, and Cancer. Frontiers in Immunology, 2018, 9, 1407.	4.8	62
88	A functional role for Smad7 in sustaining colon cancer cell growth and survival. Cell Death and Disease, 2014, 5, e1073-e1073.	6.3	61
89	TNF-Î± Producing Innate Lymphoid Cells (ILCs) Are Increased in Active Celiac Disease and Contribute to Promote Intestinal Atrophy in Mice. PLoS ONE, 2015, 10, e0126291.	2.5	61
90	Emerging immunological targets in inflammatory bowel disease. Current Opinion in Pharmacology, 2011, 11, 640-645.	3.5	59

#	Article	IF	Citations
91	Malignant gastric outlet obstruction: Which is the best therapeutic option?. World Journal of Gastroenterology, 2020, 26, 1847-1860.	3.3	59
92	Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinaseâ€“dependent induction of Socs-3. Blood, 2009, 113, 3512-3519.	1.4	57
93	Interleukin-34 sustains inflammatory pathways in the gut. Clinical Science, 2015, 129, 271-280.	4.3	57
94	Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue. Oncotarget, 2018, 9, 3432-3445.	1.8	57
95	Smad7 Expression in T cells Prevents Colitis-Associated Cancer. Cancer Research, 2011, 71, 7423-7432.	0.9	56
96	Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis. Journal of Immunology, 2017, 198, 2735-2746.	0.8	56
97	Interleukin-23 and Th17 Cells in the Control of Gut Inflammation. Mediators of Inflammation, 2009, 2009, 1-7.	3.0	54
98	T-cell-directed therapies in inflammatory bowel diseases. Clinical Science, 2010, 118, 707-715.	4.3	54
99	A phase 1 openâ€label trial shows that smad7 antisense oligonucleotide (<scp>GED</scp>0301) does not increase the risk of small bowel strictures in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 850-857.	3.7	53
100	Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation. Clinical Science, 2018, 132, 1155-1168.	4.3	53
101	Extracellular Signal-Regulated Protein Kinase Mediates Interleukin 17 (IL-17)-Induced IL-8 Secretion in Helicobacter pylori -Infected Human Gastric Epithelial Cells. Infection and Immunity, 2004, 72, 5019-5026.	2.2	51
102	Advances in understanding the role of cytokines in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 907-915.	3.0	51
103	The TGF-Î²/Smad System in IBD Pathogenesis. Inflammatory Bowel Diseases, 2015, 21, 2921-2925.	1.9	50
104	IL-21 Is a Major Negative Regulator of IRF4-Dependent Lipolysis Affecting Tregs in Adipose Tissue and Systemic Insulin Sensitivity. Diabetes, 2014, 63, 2086-2096.	0.6	49
105	Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7. Gut, 1998, 43, 620-628.	12.1	48
106	Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation. Molecular Nutrition and Food Research, 2017, 61, 1601066.	3.3	48
107	Interleukin-21 sustains inflammatory signals that contribute to sporadic colon tumorigenesis. Oncotarget, 2015, 6, 9908-9923.	1.8	47
108	Role of TGF-Beta and Smad7 in Gut Inflammation, Fibrosis and Cancer. Biomolecules, 2021, 11, 17.	4.0	47

#	Article	IF	Citations
109	Interleukin-34 Induces Cc-chemokine Ligand 20 in Gut Epithelial Cells. Journal of Crohn's and Colitis, 2016, 10, 87-94.	1.3	46
110	Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. Molecular Metabolism, 2020, 36, 100976.	6.5	46
111	Manipulation of cytokines in the management of patients with inflammatory bowel disease. Annals of Medicine, 2000, 32, 552-560.	3.8	45
112	IL-25 prevents and cures fulminant hepatitis in mice through a myeloid-derived suppressor cell-dependent mechanism. Hepatology, 2013, 58, 1436-1450.	7.3	45
113	Interleukin-25 production is differently regulated by TNF-Î± and TGF-Î²1 in the human gut. Mucosal Immunology, 2011, 4, 239-244.	6.0	44
114	Preclinical Studies of a Specific PPARÎ³ Modulator in the Control of Skin Inflammation. Journal of Investigative Dermatology, 2014, 134, 1001-1011.	0.7	44
115	IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN-Î³â€“Dependent Epidermal Hyperplasia. Journal of Immunology, 2011, 186, 5435-5442.	0.8	43
116	Constitutive Activation of the Signal Transducer and Activator of Transcription Pathway in Celiac Disease Lesions. American Journal of Pathology, 2003, 162, 1845-1855.	3.8	42
117	Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflammatory Bowel Diseases, 2012, 18, 449-459.	1.9	42
118	Tbet Expression in Regulatory T Cells Is Required to Initiate Th1-Mediated Colitis. Frontiers in Immunology, 2019, 10, 2158.	4.8	42
119	Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death and Differentiation, 2006, 13, 202-211.	11.2	41
120	Association between â^'308 G/A TNF-Î±Polymorphism and Appendicular Skeletal Muscle Mass Index as a Marker of Sarcopenia in Normal Weight Obese Syndrome. Disease Markers, 2013, 35, 615-623.	1.3	41
121	Ultrasonography Tight Control and Monitoring in Crohnâ€™s Disease During Different Biological Therapies: A Multicenter Study. Clinical Gastroenterology and Hepatology, 2022, 20, e711-e722.	4.4	41
122	Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells. Carcinogenesis, 2014, 35, 1536-1546.	2.8	40
123	Interleukin-21 triggers effector cell responses in the gut. World Journal of Gastroenterology, 2010, 16, 3638.	3.3	40
124	Th17 immune response in IBD: A new pathogenic mechanism. Journal of Crohn's and Colitis, 2008, 2, 291-295.	1.3	39
125	Interleukin-25: A two-edged sword in the control of immune-inflammatory responses. Cytokine and Growth Factor Reviews, 2010, 21, 471-475.	7.2	39
126	Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohnâ€™s Disease: An International Multicenter Study. Inflammatory Bowel Diseases, 2018, 24, 2001-2006.	1.9	39

#	Article	IF	Citations
127	Response Assessed by Ultrasonography as Target of Biological Treatment for Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2030-2037.	4.4	39
128	Aryl hydrocarbon receptorâ€driven signals inhibit collagen synthesis in the gut. European Journal of Immunology, 2016, 46, 1047-1057.	2.9	38
129	Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohnâ€™s disease. Therapeutic Advances in Gastroenterology, 2016, 9, 527-532.	3.2	37
130	IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunology, 2008, 1, 110-115.	6.0	36
131	Tissue Inhibitor of Metalloproteinase-3 Regulates Inflammation in Human and Mouse Intestine. Gastroenterology, 2012, 143, 1277-1287.e4.	1.3	36
132	Th17 Cytokines in Inflammatory Bowel Diseases: Discerning the Good from the Bad. International Reviews of Immunology, 2013, 32, 526-533.	3.3	35
133	Impact of patient characteristics on the clinical efficacy of mongersen (GEDâ€0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 717-724.	3.7	35
134	RORÎ³t-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells. Cancer Immunology Research, 2018, 6, 1082-1092.	3.4	35
135	IL-21 in the pathogenesis and treatment of skin diseases. Journal of Dermatological Science, 2010, 60, 61-66.	1.9	34
136	Targets for new immunomodulation strategies in inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 11-14.	5.8	34
137	Association Between Celiac Disease and Cancer. International Journal of Molecular Sciences, 2020, 21, 4155.	4.1	33
138	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmunity Reviews, 2020, 19, 102574.	5.8	32
139	Targeting interleukin-21 in inflammatory diseases. Expert Opinion on Therapeutic Targets, 2011, 15, 695-702.	3.4	31
140	Analysis of the cytokine profile in the duodenal mucosa of refractory coeliac disease patients. Clinical Science, 2014, 126, 451-458.	4.3	31
141	Molecular basis of the potential of mesalazine to prevent colorectal cancer. World Journal of Gastroenterology, 2008, 14, 4434.	3.3	31
142	Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis, 2008, 29, 1258-1266.	2.8	30
143	Colorectal Cancer Chemoprevention by Mesalazine and Its Derivatives. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-6.	3.0	30
144	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflammatory Bowel Diseases, 2019, 25, 1805-1812.	1.9	30

#	Article	IF	Citations
145	Interleukin-34 Stimulates Gut Fibroblasts to Produce Collagen Synthesis. Journal of Crohn's and Colitis, 2020, 14, 1436-1445.	1.3	30
146	The safety of non-biological treatments in Ulcerative Colitis. Expert Opinion on Drug Safety, 2017, 16, 779-789.	2.4	29
147	Role of Interleukin-34 in Cancer. Cancers, 2020, 12, 252.	3.7	29
148	Metalloproteinases in Inflammatory Bowel Diseases. Journal of Inflammation Research, 2021, Volume 14, 1029-1041.	3.5	29
149	Interferon-gamma (IFN-Î³) and prostaglandin E2 (PGE2) regulate differently IL-12 production in human intestinal lamina propria mononuclear cells (LPMC). Clinical and Experimental Immunology, 1999, 117, 469-475.	2.6	28
150	Interleukin-21: A New Mediator of Inflammation in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	28
151	IL-21 as a therapeutic target in inflammatory disorders. Expert Opinion on Therapeutic Targets, 2014, 18, 1329-1338.	3.4	28
152	Idiopathic acute pancreatitis: a review on etiology and diagnostic work-up. Clinical Journal of Gastroenterology, 2019, 12, 511-524.	0.8	28
153	A Functional Role of Flip in Conferring Resistance of Crohnâ€™s Disease Lamina Propria Lymphocytes to FAS-Mediated Apoptosis. Gastroenterology, 2006, 130, 389-397.	1.3	27
154	WhatÊ¼s the next best cytokine target in IBD?. Inflammatory Bowel Diseases, 2012, 18, 2180-2189.	1.9	27
155	Involvement of interleukin-15 and interleukin-21, two Î³-chain-related cytokines, in celiac disease. World Journal of Gastroenterology, 2009, 15, 4609.	3.3	27
156	CCL20 Is Negatively Regulated by TGF-Î²1 in Intestinal Epithelial Cells and Reduced in Crohnâ€™s Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide. Journal of Crohn's and Colitis, 2016, 11, jjw191.	1.3	26
157	Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease. Clinical Science, 2015, 129, 1107-1113.	4.3	24
158	Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges. Drugs, 2015, 75, 723-730.	10.9	24
159	Oligonucleotidesâ€”A Novel Promising Therapeutic Option for IBD. Frontiers in Pharmacology, 2019, 10, 314.	3.5	24
160	Cadherin-11 Is a Regulator of Intestinal Fibrosis. Journal of Crohn's and Colitis, 2020, 14, 406-417.	1.3	24
161	5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. European Journal of Cancer, 2006, 42, 2609-2616.	2.8	23
162	Role of Smad7 in inflammatory bowel diseases. World Journal of Gastroenterology, 2012, 18, 5664.	3.3	23

#	Article	IF	Citations
163	Interleukinâ€21 in chronic inflammatory diseases. BioFactors, 2013, 39, 368-373.	5.4	23
164	Impairment of ghrelin synthesis inHelicobacter pylori-colonized stomach: New clues for the pathogenesis ofH. pylori-related gastric inflammation. World Journal of Gastroenterology, 2014, 20, 639.	3.3	23
165	Serum regenerating isletâ€derived 3â€alpha is a biomarker of mucosal enteropathies. Alimentary Pharmacology and Therapeutics, 2014, 40, 974-981.	3.7	23
166	Lumen-apposing metal stents for malignant biliary obstruction: Is this the ultimate horizon of our experience?. World Journal of Gastroenterology, 2019, 25, 3857-3869.	3.3	23
167	Interleukin-21 (IL-21) Controls Inflammatory Pathways in the Gut. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2007, 7, 288-291.	1.2	22
168	Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice. Inflammatory Bowel Diseases, 2018, 24, 1213-1224.	1.9	22
169	Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacological Research, 2020, 161, 105206.	7.1	22
170	An Overview of the Role of Innate Lymphoid Cells in Gut Infections and Inflammation. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	21
171	The Fragile X Mental Retardation Protein Regulates RIPK1 and Colorectal Cancer Resistance to Necroptosis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 639-658.	4.5	21
172	Peritoneal expression of matrilysin helps identify early post-operative recurrence of colorectal cancer. Oncotarget, 2015, 6, 13402-13415.	1.8	21
173	Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders. Nutrients, 2022, 14, 260.	4.1	21
174	Role of IL-21 in inflammatory bowel disease. Expert Review of Clinical Immunology, 2010, 6, 537-541.	3.0	20
175	Celiac Disease-Related Inflammation Is Marked by Reduction of Nkp44/Nkp46-Double Positive Natural Killer Cells. PLoS ONE, 2016, 11, e0155103.	2.5	20
176	Smad7 knockdown activates protein kinase RNA-associated eIF2Î± pathway leading to colon cancer cell death. Cell Death and Disease, 2017, 8, e2681-e2681.	6.3	20
177	Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK)ÂInhibitors . Clinical and Experimental Gastroenterology, 2020, Volume 13, 131-139.	2.3	20
178	Role of Interleukin-21 in Inflammation and Allergy. Inflammation and Allergy: Drug Targets, 2007, 6, 63-68.	1.8	19
179	Difficult Biliary Stones: A Comprehensive Review of New and Old Lithotripsy Techniques. Medicina (Lithuania), 2022, 58, 120.	2.0	19
180	Activated STAT4 and a Functional Role for IL-12 in Human Peyerâ€™s Patches. Journal of Immunology, 2003, 170, 300-307.	0.8	18

#	Article	IF	Citations
181	Sampling of proximal and distal duodenal biopsies in the diagnosis and monitoring of celiac disease. Digestive and Liver Disease, 2014, 46, 323-329.	0.9	18
182	A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction. Cell Reports, 2016, 16, 731-743.	6.4	18
183	No Change in the Mucosal Gut Microbiome is Associated With Celiac Disease-Specific Microbiome Alteration in Adult Patients. American Journal of Gastroenterology, 2016, 111, 1659-1661.	0.4	18
184	Interleukin-34 Enhances the Tumor Promoting Function of Colorectal Cancer-Associated Fibroblasts. Cancers, 2020, 12, 3537.	3.7	18
185	High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 1387.	2.4	18
186	Bacteria and mucosal immunity. Digestive and Liver Disease, 2006, 38, S256-S260.	0.9	17
187	2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression. Molecular Cancer Therapeutics, 2011, 10, 1969-1981.	4.1	17
188	Smad7 positively regulates keratinocyte proliferation in psoriasis. British Journal of Dermatology, 2017, 177, 1633-1643.	1.5	17
189	Progranulin sustains <scp>STAT</scp>3 hyperâ€activation and oncogenic function in colorectal cancer cells. Molecular Oncology, 2019, 13, 2142-2159.	4.6	17
190	Smad7 and Colorectal Carcinogenesis: A Double-Edged Sword. Cancers, 2019, 11, 612.	3.7	17
191	Onset of ulcerative colitis during SARS-CoV-2 infection. Digestive and Liver Disease, 2020, 52, 1228-1229.	0.9	17
192	mTOR sustains inflammatory response in celiac disease. Scientific Reports, 2020, 10, 10798.	3.3	17
193	Inhibition of Colon Carcinogenesis by 2-Methoxy-5-Amino-N-Hydroxybenzamide, a Novel Derivative of Mesalamine. Gastroenterology, 2010, 138, 221-230.	1.3	16
194	Smad7 Knockdown Restores Aryl Hydrocarbon Receptor-mediated Protective Signals in the Gut. Journal of Crohn's and Colitis, 2016, 10, 670-677.	1.3	16
195	High Smad7 sustains inflammatory cytokine response in refractory coeliac disease. Immunology, 2017, 150, 356-363.	4.4	16
196	The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man. Digestive Diseases, 2015, 33, 113-119.	1.9	15
197	Tofacitinib for the treatment of ulcerative colitis. Expert Opinion on Investigational Drugs, 2016, 25, 991-997.	4.1	15
198	Protective Effects of Aryl Hydrocarbon Receptor Signaling in Celiac Disease Mucosa and in Poly I:C-Induced Small Intestinal Atrophy Mouse Model. Frontiers in Immunology, 2019, 10, 91.	4.8	15

#	Article	IF	Citations
199	Feasibility and cost effectiveness of ambulatory laparoscopic cholecystectomy. A retrospective cohort study. Annals of Medicine and Surgery, 2020, 55, 56-61.	1.1	15
200	Low Frequency of Acute Pancreatitis in Hospitalized COVID-19 Patients. Pancreas, 2021, 50, 393-398.	1.1	15
201	GATA6 Deficiency Leads to Epithelial Barrier Dysfunction and Enhances Susceptibility to Gut Inflammation. Journal of Crohn's and Colitis, 2022, 16, 301-311.	1.3	15
202	Overview of Role of the Immune System in the Pathogenesis of Inflammatory Bowel Disease. Advances in Experimental Medicine and Biology, 2006, 579, 98-107.	1.6	15
203	The opposing roles of IL-21 and TGFÎ²1 in chronic inflammatory bowel disease. Biochemical Society Transactions, 2011, 39, 1061-1066.	3.4	14
204	Reprogramming the Immune System in IBD. Digestive Diseases, 2012, 30, 392-395.	1.9	14
205	Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases. Digestive and Liver Disease, 2013, 45, 552-555.	0.9	14
206	Inflammatory bowel disease: new therapies from antisense oligonucleotides. Annals of Medicine, 2018, 50, 361-370.	3.8	14
207	Interleukin-21 in Immune and Allergic Diseases. Inflammation and Allergy: Drug Targets, 2012, 11, 313-319.	1.8	13
208	Reciprocal Regulation Between Smad7 and Sirt1 in the Gut. Frontiers in Immunology, 2018, 9, 1854.	4.8	13
209	Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide. Cancer Letters, 2019, 462, 1-11.	7.2	13
210	Macrophages produce and functionally respond to interleukin-34 in colon cancer. Cell Death Discovery, 2020, 6, 117.	4.7	13
211	Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells. Cancers, 2020, 12, 1314.	3.7	13
212	A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohnâ€™s Disease: A Phase II, Open-Label Study. BioDrugs, 2021, 35, 325-336.	4.6	13
213	Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut, 2008, 57, 1674-1680.	12.1	12
214	Pathogenic role of interleukin-21 in psoriasis. Cell Cycle, 2009, 8, 3629-3630.	2.6	12
215	Disruption of inflammatory signals by cytokineâ€targeted therapies for inflammatory bowel diseases. British Journal of Pharmacology, 2012, 165, 820-828.	5.4	12
216	Targeting IL-23 in Crohnâ€™s disease. Expert Review of Clinical Immunology, 2018, 14, 907-913.	3.0	12

#	Article	IF	Citations
217	Oligonucleotide-Based Therapies for Inflammatory Bowel Disease. BioDrugs, 2018, 32, 331-338.	4.6	12
218	High SMAD7 and p-SMAD2,3 expression is associated with environmental enteropathy in children. PLoS Neglected Tropical Diseases, 2018, 12, e0006224.	3.0	12
219	Low frequency of COVID-19 in inflammatory bowel diseases. Digestive and Liver Disease, 2020, 52, 1234-1235.	0.9	12
220	Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis. European Journal of Clinical Pharmacology, 2020, 76, 409-418.	1.9	12
221	The Deubiquitinating Enzyme OTUD5 Sustains Inflammatory Cytokine Response in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 122-132.	1.3	12
222	Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases. Current Drug Metabolism, 2016, 17, 303-306.	1.2	12
223	Interleukin-25 fails to activate STAT6 and induce alternatively activated macrophages. Immunology, 2011, 132, 66-77.	4.4	11
224	Viruses in Cancers of the Digestive System: Active Contributors or Idle Bystanders?. International Journal of Molecular Sciences, 2020, 21, 8133.	4.1	11
225	Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer. International Journal of Molecular Sciences, 2021, 22, 3922.	4.1	11
226	Interleukin-21 in T cell-mediated diseases. Discovery Medicine, 2009, 8, 113-7.	0.5	11
227	Precision Medicine in Inflammatory Bowel Diseases. Frontiers in Pharmacology, 2021, 12, 653924.	3.5	10
228	Albendazole negatively regulates keratinocyte proliferation. Clinical Science, 2020, 134, 907-920.	4.3	9
229	Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?. Inflammation and Allergy: Drug Targets, 2011, 10, 47-53.	1.8	8
230	<scp>H</scp>elicobacter pylori Infection Associates with a Mucosal Downregulation of Ghrelin, Negative Regulator of Th1â€€Cell Responses. Helicobacter, 2013, 18, 406-412.	3.5	8
231	Impact of surgery on quality of life in Crohnâ€™s disease: short- and mid-term follow-up. Updates in Surgery, 2020, 72, 773-780.	2.0	8
232	Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. Scandinavian Journal of Gastroenterology, 2021, 56, 498-504.	1.5	8
233	Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment. Nucleic Acid Therapeutics, 2022, 32, 312-320.	3.6	8
234	Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?. Molecular Diagnosis and Therapy, 2022, 26, 477-481.	3.8	8

#	Article	IF	Citations
235	Th17-cytokine blockers as a new approach for treating inflammatory bowel disease. Annals of Medicine, 2011, 43, 172-178.	3.8	7
236	Targeting Integrins and Adhesion Molecules to Combat Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1885-1889.	1.9	7
237	Sphingosine-1-phosphate receptor: a novel therapeutic target in ulcerative colitis. Expert Review of Clinical Immunology, 2016, 12, 1137-1139.	3.0	7
238	High Smad7 in the early post-operative recurrence of Crohnâ€™s disease. Journal of Translational Medicine, 2020, 18, 395.	4.4	7
239	TGF-Î² activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases. Pharmacological Research, 2020, 155, 104757.	7.1	7
240	Multiple hepatic and brain abscesses caused by Parvimonas micra: A case report and literature review. Anaerobe, 2021, 69, 102366.	2.1	7
241	Interleukin-34 promotes tumorigenic signals for colon cancer cells. Cell Death Discovery, 2021, 7, 245.	4.7	7
242	Expression of Receptors for SARS-CoV-2 in the Gut of Patients with Inflammatory Bowel Disease. Gut and Liver, 2020, 14, 530-531.	2.9	7
243	Tips and tricks for the diagnosis and management of biliary stenosis-state of the art review. World Journal of Gastrointestinal Endoscopy, 2021, 13, 473-490.	1.2	7
244	Poorly Cohesive Carcinoma of the Nonampullary Small Intestine. American Journal of Surgical Pathology, 2022, 46, 498-508.	3.7	7
245	Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon. Computational and Structural Biotechnology Journal, 2021, 19, 6080-6089.	4.1	7
246	Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab. Journal of Clinical Medicine, 2022, 11, 1679.	2.4	7
247	Changes in the mucosal expression of interleukin 15 inHelicobacter pylori-associated gastritis. FEMS Immunology and Medical Microbiology, 1999, 24, 233-238.	2.7	6
248	Long COVID in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021, 10, 5575.	2.4	6
249	Targeting IL-34/MCSF-1R Axis in Colon Cancer. Frontiers in Immunology, 0, 13, .	4.8	6
250	IL-4 hyporesponsiveness of Crohn's disease mucosal T lymphocytes: a response of polarised Th1 cells?. Digestive and Liver Disease, 2000, 32, 495-497.	0.9	5
251	Local immune activity in acute coronary syndrome: oxLDL abrogates LPS-tolerance in mononuclear cells isolated from culprit lesion. International Journal of Cardiology, 2013, 169, 44-51.	1.7	5
252	Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. Journal of Clinical Medicine, 2020, 9, 385.	2.4	5

#	Article	IF	Citations
253	Efficacy of hemostatic powders as monotherapy or rescue therapy in gastrointestinal bleeding related to neoplastic or non-neoplastic lesions. Scandinavian Journal of Gastroenterology, 2021, 56, 1506-1513.	1.5	5
254	<scp>PIK</scp>3<scp>CA</scp> c.3140A>G mutation in a patient with suspected Proteus Syndrome: a case report. Clinical Case Reports (discontinued), 2018, 6, 1358-1363.	0.5	4
255	A Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohnâ€™s Disease. Biomedicines, 2020, 8, 234.	3.2	4
256	Minimal Open Access Ileocolic Resection in Complicated Crohnâ€™s Disease of the Terminal Ileum. Gastroenterology Research and Practice, 2020, 2020, 1-6.	1.5	4
257	Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2020, 11, 585732.	3.5	4
258	Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. European Journal of Gastroenterology and Hepatology, 2021, 33, 977-982.	1.6	4
259	Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut. Frontiers in Immunology, 2022, 13, 873332.	4.8	4
260	Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2020, 9, 2126.	2.4	3
261	Clinical care pathway program versus open-access system: a study on appropriateness, quality, and efficiency in the delivery of colonoscopy in the colorectal cancer. Internal and Emergency Medicine, 2021, 16, 1197-1206.	2.0	3
262	Contraindications for whole body vibration training: a case of nephrolitiasis. Journal of Sports Medicine and Physical Fitness, 2007, 47, 443-5.	0.7	3
263	Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. Cancers, 2022, 14, 1730.	3.7	3
264	Why are molecular mechanisms of immune activation important in IBD?. Inflammatory Bowel Diseases, 2008, 14, S106-S107.	1.9	2
265	Investigational cytokine-targeted therapies for ulcerative colitis. Expert Opinion on Investigational Drugs, 2013, 22, 1123-1132.	4.1	2
266	Interleukin-17 A-E. , 2017, , 549-572.		2
267	No effect of a liquid diet in the management of patients with stricturing Crohnâ€™s disease. International Journal of Colorectal Disease, 2020, 35, 1881-1885.	2.2	2
268	Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases . Biologics: Targets and Therapy, 2020, Volume 14, 47-51.	3.2	2
269	2-Methoxy-5-amino-N-hydroxybenzamide, a derivative of mesalamine, inhibits colon cancer cell growth through cyclo-oxygenase-2-dependent and -independent mechanisms. Clinical Science, 2012, 123, 295-306.	4.3	1
270	The Role of IL-21 in Chronic Inflammatory Skin Diseases. Current Dermatology Reports, 2013, 2, 11-17.	2.1	1

#	Article	IF	Citations
271	The impact of translational research on gastroenterology. Digestive and Liver Disease, 2014, 46, 293-294.	0.9	1
272	Contrastâ€“enhanced endoscopic ultrasound diagnosis of the intraductal papillary mucinous neoplasm. Clinical Journal of Gastroenterology, 2020, 13, 120-126.	0.8	1
273	Endoscopic retrieval through a lumen-apposing metal stent of a biflanged metal stent that had been released into a peripancreatic fluid collection. Endoscopy, 2020, 52, E275-E276.	1.8	1
274	Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis. Journal of Clinical Medicine, 2021, 10, 1192.	2.4	1
275	Entrapment of the sciatic nerve at the linea aspera: A case report and literature review. , 2016, 7, 89.		1
276	Internal shoulder impingement in overhead athletes: an ultrasound imaging proposal. Ultrasonography, 2018, 37, 275-276.	2.3	1
277	Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. Journal of Clinical Medicine, 2021, 10, 5413.	2.4	1
278	The Smad System. Inflammatory Bowel Diseases, 2006, 12, S10.	1.9	0
279	Why are molecular mechanisms of immune activation important in IBD?. Inflammatory Bowel Diseases, 2008, 14, S106-S107.	1.9	0
280	TH17 Cells and IL-23 in Gut Inflammation. , 2011, , 257-267.		0
281	Therapy implications for the role of IL-21 in lupus. Expert Review of Clinical Immunology, 2016, 12, 487-488.	3.0	0
282	P332 Treat to target in Crohn's disease: ultrasonographic response is associated with better outcomes. Journal of Crohn's and Colitis, 2017, 11, S246-S246.	1.3	0
283	Smad7 as a Target for Immunomodulation Strategy in Inflammatory Bowel Diseases. Immunome Research, 2017, 13, .	0.1	0
284	P196 High frequency of undiagnosed mental illness in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2020, 14, S236-S237.	1.3	0
285	Idiopathic acute pancreatitis: a single-center investigation of clinical and biochemical features. Internal and Emergency Medicine, 2021, 16, 93-99.	2.0	0
286	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
287	Control of mucosal immune responses by transforming growth factor-Î². , 2007, , 29-34.		0
288	SAT0266â€…Use of conventional synthetic dmards and biological dmards in patients with enteropathic spondyloarthritis: a combined gastro-rheumatological approach. , 2018, , .		0

#	Article	IF	Citations
289	ENDOSCOPIC RETRIEVAL OF A BI-FLANGED METAL STENT RELEASED INTO A PERIPANCREATIC FLUID COLLECTION THROUGH A LUMEN-APPOSING METAL STENT. Endoscopy, 2020, 52, .	1.8	0
290	EUS-FNA/FNB AND ERCP IN THE DIAGNOSTIC WORK-UP OF BILIARY STENOSIS: A RETROSPECTIVE STUDY. Endoscopy, 2022, 54, .	1.8	0